Loading...
XLON
GSK
Market cap77bUSD
Apr 01, Last price  
1,469.00GBP
1D
0.48%
1Q
9.10%
Jan 2017
-6.89%
Name

GSK plc

Chart & Performance

D1W1MN
P/E
2,320.62
P/S
190.45
EPS
0.63
Div Yield, %
3.13%
Shrs. gr., 5y
15.60%
Rev. gr., 5y
-1.45%
Revenues
31.38b
+3.46%
21,660,000,00023,225,000,00022,716,000,00024,352,000,00028,368,000,00028,392,000,00027,387,000,00026,431,000,00026,505,000,00023,006,000,00023,923,000,00027,889,000,00030,186,000,00030,821,000,00033,754,000,00034,099,000,00034,114,000,00029,324,000,00030,328,000,00031,376,000,000
Net income
2.58b
-47.75%
4,689,000,0005,389,000,0005,214,000,0004,712,000,0005,531,000,0001,634,000,0005,261,000,0004,565,000,0005,436,000,0002,756,000,0008,422,000,000912,000,0001,532,000,0003,623,000,0004,645,000,0005,749,000,0004,385,000,0004,921,000,0004,928,000,0002,575,000,000
CFO
6.55b
-3.16%
5,587,000,0003,958,000,0005,795,000,0007,311,000,0007,841,000,0006,797,000,0006,250,000,0004,375,000,0007,222,000,0005,176,000,0002,569,000,0006,497,000,0006,918,000,0008,421,000,0008,020,000,0008,441,000,0007,952,000,0007,403,000,0006,768,000,0006,554,000,000
Dividend
Aug 15, 202415 GBP/sh
Earnings
Apr 29, 2025

Profile

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
URL
https://www.gsk.com/
IPO date
May 22, 1972
Employees
69,400
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
31,376,000
3.46%
30,328,000
3.42%
29,324,000
-14.04%
Cost of revenue
26,464,000
24,173,000
23,414,000
Unusual Expense (Income)
NOPBT
4,912,000
6,155,000
5,910,000
NOPBT Margin
15.66%
20.29%
20.15%
Operating Taxes
526,000
756,000
707,000
Tax Rate
10.71%
12.28%
11.96%
NOPAT
4,386,000
5,399,000
5,203,000
Net income
2,575,000
-47.75%
4,928,000
0.14%
4,921,000
12.22%
Dividends
(2,444,000)
(2,247,000)
(3,467,000)
Dividend yield
4.38%
3.77%
11.81%
Proceeds from repurchase of equity
20,000
10,000
25,000
BB yield
-0.04%
-0.02%
-0.09%
Debt
Debt current
2,349,000
2,813,000
3,952,000
Long-term debt
15,739,000
16,412,000
18,043,000
Deferred revenue
165,000
83,000
Other long-term liabilities
9,496,000
9,937,000
9,833,000
Net debt
13,163,000
13,464,000
16,731,000
Cash flow
Cash from operating activities
6,554,000
6,768,000
7,403,000
CAPEX
(1,399,000)
(1,314,000)
(2,258,000)
Cash from investing activities
(1,229,000)
(1,595,000)
(8,772,000)
Cash from financing activities
(4,726,000)
(5,641,000)
823,000
FCF
5,918,000
5,062,000
(3,696,000)
Balance
Cash
3,714,000
4,992,000
7,877,000
Long term investments
1,211,000
769,000
(2,613,000)
Excess cash
3,356,200
4,244,600
3,797,800
Stockholders' equity
8,559,000
9,344,000
5,208,000
Invested Capital
36,376,800
36,505,400
36,730,200
ROIC
12.04%
14.74%
11.97%
ROCE
12.24%
15.10%
14.48%
EV
Common stock shares outstanding
4,142,000
4,111,000
2,042,000
Price
13.47
-7.15%
14.50
0.88%
14.38
-11.41%
Market cap
55,772,030
-6.45%
59,617,722
103.09%
29,355,792
-10.71%
EV
68,350,030
72,529,722
45,584,792
EBITDA
7,463,000
8,449,000
8,208,000
EV/EBITDA
9.16
8.58
5.55
Interest
640,000
775,000
879,000
Interest/NOPBT
13.03%
12.59%
14.87%